Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00637793 · ClinicalTrials.gov registry record · Phase 2
Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome
A Phase 2 study, sponsored by TorreyPines Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00637793: Completed Phase 2 study, sponsored by TorreyPines Therapeutics.
NCT00637793 is a Phase 2 study that has completed, run by TorreyPines Therapeutics. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00637793, a Phase 2 study, has completed, sponsored by TorreyPines Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of NGX267 in the improvement of decreased salivary flow associated with primary or secondary Sjögren's syndrome. For each patient, the study includes four periods of treatment separated by a washout period that may range from 4 - 8 days according to patient and site discretion. Each treatment period includes two overnight stays in the clinic. One dose of study drug is taken during each treatment period
Interventions
- DRUG NGX267
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
What the finished NCT00637793 record still lists
NCT00637793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which NGX267 is the first listed.
NCT00637793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00637793 about?
NCT00637793 is a clinical study titled "Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome". The purpose of this study is to evaluate the effectiveness of NGX267 in the improvement of decreased salivary flow associated with primary or secondary Sjögren's syndrome. For each patient, the study includes four periods of treatment separated by a washout period that may range from 4 - 8 days acc...
What is the current status of trial NCT00637793?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2008-02. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00637793?
The interventions under investigation include: NGX267 (DRUG).
Who is sponsoring clinical trial NCT00637793?
This trial is sponsored by TorreyPines Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00637793's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia